Nuveen Fund Advisors buys $7,781,378 stake in Amgen (AMGN)

Amgen (AMGN) : Nuveen Fund Advisors scooped up 119 additional shares in Amgen during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Nov 14, 2016. The investment management firm now holds a total of 52,210 shares of Amgen which is valued at $7,781,378.Amgen makes up approximately 1.10% of Nuveen Fund Advisors’s portfolio.

Other Hedge Funds, Including , Lazard Asset Management reduced its stake in AMGN by selling 25,555 shares or 13.61% in the most recent quarter. The Hedge Fund company now holds 162,208 shares of AMGN which is valued at $23,750,495. Amgen makes up approx 0.05% of Lazard Asset Management’s portfolio.Smead Capital Management reduced its stake in AMGN by selling 52,713 shares or 5.83% in the most recent quarter. The Hedge Fund company now holds 851,682 shares of AMGN which is valued at $118,562,651. Amgen makes up approx 5.88% of Smead Capital Management’s portfolio.Orinda Asset Management boosted its stake in AMGN in the latest quarter, The investment management firm added 603 additional shares and now holds a total of 1,677 shares of Amgen which is valued at $264,790. Amgen makes up approx 0.23% of Orinda Asset Management’s portfolio.Baxter Bros Inc reduced its stake in AMGN by selling 600 shares or 13.78% in the most recent quarter. The Hedge Fund company now holds 3,754 shares of AMGN which is valued at $604,694. Amgen makes up approx 0.19% of Baxter Bros Inc’s portfolio.

Amgen closed down -2.13 points or -1.45% at $145.23 with 37,64,649 shares getting traded on Monday. Post opening the session at $147.05, the shares hit an intraday low of $144.9 and an intraday high of $148.35 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Amgen reported $3.02 EPS for the quarter, beating the analyst consensus estimate by $ 0.23 according to the earnings call on Oct 27, 2016. Analyst had a consensus of $2.79. The company had revenue of $5811.00 million for the quarter, compared to analysts expectations of $5702.65 million. The company’s revenue was up 1.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.72 EPS.

Many Wall Street Analysts have commented on Amgen. Mizuho Initiated Amgen on Nov 8, 2016 to “Buy”, Price Target of the shares are set at $164.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Leave a Reply

Amgen - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amgen. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.